Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and Death
Author
dc.contributor.author
Sánchez, Gina
Author
dc.contributor.author
Berrios, Daniela
Author
dc.contributor.author
Olmedo, Ivonne
Author
dc.contributor.author
Pezoa, Javier
Author
dc.contributor.author
Riquelme, Jaime A.
Author
dc.contributor.author
Montecinos, Luis
Author
dc.contributor.author
Pedrozo Cibils, Zully
Author
dc.contributor.author
Donoso Laurent, Paulina
Admission date
dc.date.accessioned
2016-12-26T19:55:36Z
Available date
dc.date.available
2016-12-26T19:55:36Z
Publication date
dc.date.issued
2016
Cita de ítem
dc.identifier.citation
PLoS ONE 11(8): e0161068 (2016)
es_ES
Identifier
dc.identifier.other
10.1371/journal.pone.0161068
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/142090
Abstract
dc.description.abstract
Inhibitors of the ubiquitin-proteasome system improve hemodynamic parameters and decrease the infarct size after ischemia reperfusion. The molecular basis of this protection is not fully understood since most available data report inhibition of the 26 proteasome after ischemia reperfusion. The decrease in cellular ATP levels during ischemia leads to the dissociation of the 26S proteasome into the 19S regulatory complex and the 20S catalytic core, which results in protein degradation independently of ubiquitination. There is scarce information on the activity of the 20S proteasome during cardiac ischemia. Accordingly, the aim of this work was to determine the effects of 30 minutes of ischemia, or 30 min of ischemia followed by 60 minutes of reperfusion on the three main peptidase activities of the 20S proteasome in Langendorff perfused rat hearts. We found that 30 min of ischemia produced a significant increase in the chymotrypsin-like activity of the proteasome, without changes in its caspase-like or trypsin-like activities. In contrast, all three activities were decreased upon reperfusion. Ixazomib, perfused before ischemia at a concentration that reduced the chymotrypsin-like activity to 50% of the control values, without affecting the other proteasomal activities, improved the hemodynamic parameters upon reperfusion and decreased the infarct size. Ixazomib also prevented the 50% reduction in RyR2 content observed after ischemia. The protection was lost, however, when simultaneous inhibition of chymotrypsin-like and caspase-like activities of the proteasome was achieved at higher concentration of ixazomib. Our results suggest that selective inhibition of chymotrypsin-like activity of the proteasome during ischemia preserves key proteins for cardiomyocyte function and exerts a positive impact on cardiac performance after reperfusion.
es_ES
Patrocinador
dc.description.sponsorship
Fondo Nacional de Desarrollo Cientifico y Tecnologico, FONDECYT grant
1110257
1130407
1150887
3140449
3160298